Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 881-887

  Antachopoulos, Charalampos ^a   Meletiadis, Joseph ^a   Sein, Tin ^a   Roilides, Emmanuel ^a,b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MENADIONE; NITROBLUE TETRAZOLIUM;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG EFFECT; DRUG RESPONSE; FUNGAL METABOLISM; FUNGUS CULTURE; FUNGUS ISOLATION; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; TETRAZOLIUM SALTS; VITAMIN K 3;

EID: 33847685254     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01160-06     Document Type: Article

References (29)

1. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:2310-2318.
2. Antachopoulos, C., J. Meletiadis, E. Roilides, T. Sein, D. A. Sutton, B. L. Wickes, M. G. Rinaldi, W. G. Merz, Y. R. Shea, and T. J. Walsh. 2006. Relationship between metabolism and biomass of medically important zygomycetes. Med. Mycol. 44:429-438.
3. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.
4. Barchiesi, F., E. Spreghini, A. Santinelli, A. W. Fothergill, S. Fallani, E. Manso, E. Pisa, D. Giannini, A. Novelli, M. I. Cassetta, T. Mazzei, M. G. Rinaldi, and G. Scalise. 2005. Efficacy of caspofungin against Aspergillus terreus. Antimicrob. Agents Chemother. 49:5133-5135.
5. Bowman, J. C., G. K. Abruzzo, A. M. Flattery, C. J. Gill, E. J. Hickey, M. J. Hsu, J. Nielsen Kahn, P. A. Liberator, A. S. Misura, B. A. Pelak, T. C. Wang, and C. M. Douglas. 2006. Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus niduluns. Antimicrob. Agents Chemother. 50:4202-4205.
6. Burnham, K. P., and A. D. 2002. model selection and multimodel inference; a practical information-theoretic approach. 2nd ed. Springer-Verlag, New York, NY.
7. Cacciapuoti, A., J. Halpern, C. Mendrick, C. Norris, R. Patel, and D. Loebenberg. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. 50:2587-2590.
8. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
9. Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409.
10. Gardiner, R. E., P. Souteropoulos, S. Park, and D. S. Perlin. 2005. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(Suppl. 1):S299-S305.
11. Kartsonis, N. A., J. Nielsen, and C. M. Douglas. 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist. Update 6:197-218.
12. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
13. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
14. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
15. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5- [(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
16. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
17. Motulsky, H. J., and A. Christopoulos. 2003. Complex dose-response curves, p. 290-295. In H. J. Motulsky and A. Christopoulos (ed.), Fitting models to biological data using linear and nonlinear regression. GraphPad Software, Inc., San Diego, CA.
18. Motulsky, H. J., and A. Christopoulos. 2003. Introduction to dose-response curves, p. 256-265. In H. J. Motulsky and A. Christopoulos (ed.). Fitting models to biological data using linear and nonlinear regression. GraphPad Software, Inc., San Diego, CA.
19. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Document M38-A. NCCLS, Pennsylvania, PA.
20. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W . A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
21. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropcnic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
22. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
23. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
24. Stevens, D. A., T. C. White, D. S. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178.
25. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
26. van Vianen, W., S. de Marie, M. T. ten Kate, R. A. Mathot, and I. A. Bakker-Woudenberg. 2006. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 57: 732-740.
27. Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.
28. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
29. Yekutiel, A., I. Shalit, Y. Shadkchan, and N. Osherov. 2004. In vitro activity of caspofungin combined with sulfamcthoxazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 48:3279-3283.